NASDAQ NMS - GLOBAL MARKET · BDSX
-2.99% · -$0.7900 · Vol 96.0K
After hours · updated 16:00:28 ET
Biodesix Inc

Biodesix Inc

Health Care
$25.63
Card
Relationship Map

Follow $BDSX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $BDSX by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology

snapshot unavailable for BDSX. Cause unavailable.

BDSX
Biodesix Inc
Stale score · Wed Oct 7 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Highest qualified

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

78/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Stale score · Wed Oct 7 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BDSX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BDSX catalysts
About Biodesix Inc
SERVICES-MEDICAL LABORATORIES
Listed since
2020
Employees
334
Country
US

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$26.24
Day high
$26.50
Day low
$25.10
Previous close
$26.42
52W high
$30.60
-16.24% from high
52W low
$5.46
80% of range
Market cap
$278.8M
EPS
$-3.1688
Beta
1.02
Shares out
10.6M
Volume
96K
0.97× rel vol
Avg volume
99.2K
VWAP
$25.52
Price history computed in-house
1W
-6.22%
1M
-3.76%
3M
+19.65%
1Y
+230.71%
YTD
+276.91%
SMA 50 $26.31 · below
SMA 200 $17.32 · above
52W position 80%

BDSX overview

Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file
Loading financial statements
Loading BDSX Form 4 filings
Public disclosures

Congress activity in BDSX

No receipt-qualified filings found.

Federal contracts

BDSX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BDSX in this window.
Lobbying spend

BDSX lobbying filings, year to date.

Registered lobbying filings matched to Biodesix Inc.

$90.0K
Refresh interval: 12hSource: LDA disclosure filings
Medicare/Medicaid Health Issues
Filing
$30.0K
BIODESIX INC.

TODD STRATEGY GROUP

Jul 20, 2026
Filing
$30.0K
BIODESIX INC.

TODD STRATEGY GROUP

Apr 20, 2026
Filing
$30.0K
BIODESIX INC.

TODD STRATEGY GROUP

Jan 20, 2026
Loading news for BDSX
Analyst ratings
Sovereign unlock shows live analyst consensus for BDSX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.